GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GRI Bio Inc (NAS:GRI) » Definitions » PB Ratio

GRI Bio (GRI Bio) PB Ratio : 0.33 (As of Jun. 06, 2024)


View and export this data going back to 2023. Start your Free Trial

What is GRI Bio PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-06), GRI Bio's share price is $0.288. GRI Bio's Book Value per Share for the quarter that ended in Mar. 2024 was $0.88. Hence, GRI Bio's PB Ratio of today is 0.33.

The historical rank and industry rank for GRI Bio's PB Ratio or its related term are showing as below:

GRI' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 699
Current: 0.33

During the past 3 years, GRI Bio's highest PB Ratio was 699.00. The lowest was 0.00. And the median was 0.00.

GRI's PB Ratio is ranked better than
96.03% of 1310 companies
in the Biotechnology industry
Industry Median: 2.535 vs GRI: 0.33

During the past 12 months, GRI Bio's average Book Value Per Share Growth Rate was 1098.60% per year.

Back to Basics: PB Ratio


GRI Bio PB Ratio Historical Data

The historical data trend for GRI Bio's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRI Bio PB Ratio Chart

GRI Bio Annual Data
Trend Dec21 Dec22 Dec23
PB Ratio
- - 6.72

GRI Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only - 3.11 2.06 6.72 0.87

Competitive Comparison of GRI Bio's PB Ratio

For the Biotechnology subindustry, GRI Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GRI Bio's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GRI Bio's PB Ratio distribution charts can be found below:

* The bar in red indicates where GRI Bio's PB Ratio falls into.



GRI Bio PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

GRI Bio's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=0.288/0.875
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


GRI Bio  (NAS:GRI) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


GRI Bio PB Ratio Related Terms

Thank you for viewing the detailed overview of GRI Bio's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GRI Bio (GRI Bio) Business Description

Traded in Other Exchanges
N/A
Address
2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.
Executives
David Leslie Szekeres director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121
Roelof Rongen director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Camilla V Simpson director 20 ELAINE AVE., MILL VALLEY CA 94941
Albert Agro officer: Chief Medical Officer 828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9
Walter Marc Hertz director, 10 percent owner, officer: Chief Executive Officer 2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Vipin Chaturvedi officer: Chief Scientific Officer 2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Joseph E Payne director 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Leanne M. Kelly officer: Chief Financial Officer C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Marella Thorell director 1226 CHARTER LANE, AMBLER PA 19002
Arcturus Therapeutics Holdings Inc. 10 percent owner 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Penny Toren officer: SVP, Regul Affairs & Prog Mgmt C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Ofir Levi director C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Richard Ammer director, 10 percent owner C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Pharma Gmbh Salmon 10 percent owner SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052

GRI Bio (GRI Bio) Headlines

From GuruFocus